Advertisement

Development and Internal Validation of a nomogram predicting overall survival based on Log ODDS of positive lymph-nodes for post radical cystectomy patients in muscle invasive carcinoma of bladder.

Published:November 24, 2022DOI:https://doi.org/10.1016/j.clgc.2022.11.018

      OBJECTIVE

      To develop and validate a nomogram based on LODDS (Log ODDS of positive lymph-nodes) for prediction of overall survival (OS) in post radical cystectomy (RC) patients of muscle invasive bladder cancer (MIBC).

      METHODS

      Data was retrospectively collected from 282 cases of MIBC that underwent RC from 2011 to 2017 at our institute. Significant independent predictors were identified using Cox regression model and incorporated into a nomogram to predict 1, 2, and 4-year OS.

      RESULTS

      Multivariate analysis showed that Neo-Adjuvant Chemo-Therapy (NACT) (p <0.001), LODDS (p < 0.001), T-stage (p=0.001), CCI (Charlson Comorbidity Index) (p=0.034) and grade (p=0.003) were independent predictors of OS. The C-index of nomogram (0.740) was higher than that of the American Joint Committee on Cancer (AJCC) staging system (0.614). The bias-corrected calibration plots showed that the predicted risks were in excellent accordance with the actual risks. The results of NRI, IDI, and DCA exhibited superior predictive capability and higher clinical use of the nomogram.

      CONCLUSION

      A simple, easy to use nomogram to predict OS in cases of MIBC has been constructed. To best of our knowledge, LODDS has been incorporated for the first time. It has superior predictive ability and higher clinical use than AJCC system. It would help the clinicians for better patient counselling, planning follow-up strategies and designing a clinical trial for newer adjuvant therapy (e.g. immunotherapy) in post radical cystectomy patients of MIBC.

      Micro-Abstract

      Nomogram prediction of overall survival that includes LODDS in carcinoma bladder.
      Retrospective cohort study of 282 cases from a tertiary care centre.
      The nomogram has superior predictive ability and higher clinical use than AJCC system.
      It will help clinicians for better patient counselling, planning follow-up strategies and designing clinical trials for newer adjuvant therapy (e.g. immunotherapy) in patients of MIBC.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Sung H
        • Ferlay J
        • Siegel RL
        • et al.
        Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
        CA Cancer J Clin. 2021; 71: 209-249
        • Manley KV
        • Hubbard R
        • Swallow D
        • et al.
        Risk factors for development of primary bladder squamous cell carcinoma.
        Ann R Coll Surg Engl. 2017 Feb; 99; : 155-160
        • Paner GP
        • Stadler WM
        • Hansel DE
        • et al.
        Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers.
        Eur Urol. 2018 Apr; 73: 560-569
        • Patel KN
        • Salunke A
        • Bhatt S
        • et al.
        Log ODDS (LODDS) of positive lymph nodes as a predictor of overall survival in squamous cell carcinoma of the penis.
        J Surg Oncol. 2021 May; 123: 1836-1844
        • Qiu MZ
        • Qiu HJ
        • Wang ZQ
        • et al.
        The tumor-log odds of positive lymph nodes-metastasis staging system, a promising new staging system for gastric cancer after D2 resection in China.
        PLoS One. 2012; 7: e31736
        • Zhou R
        • Zhang J
        • Sun H
        • et al.
        Comparison of three lymph node classifications for survival prediction in distant metastatic gastric cancer.
        Int J Surg. 2016 Nov; 35: 165-171
        • Arslan N.C.
        • Sokmen S.
        • Canda A.E.
        • et al.
        The prognostic impact of the log odds of positive lymph nodes in colon cancer.
        Colorectal Disease : official J. Assoc. Coloproctology G. B. Irel. 2014; 16: 0386-0392
        • Shariat SF
        • Karakiewicz PI
        • Suardi N
        • et al.
        Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature.
        Clin Cancer Res. 2008 Jul 15; 14: 4400-4407
        • Sherif Amir
        • Holmberg Lars
        • Rintala Erkki
        • et al.
        Neoadjuvant Cisplatinum Based Combination Chemotherapy in Patients with Invasive Bladder Cancer: A Combined Analysis of Two Nordic Studies.
        European Urology. 2004; 45: 297-303
        • Zhang Y
        • Yk Hong
        • Dw Zhuang
        • et al.
        Bladder cancer survival nomogram: Development and validation of a prediction tool, using the SEER and TCGA databases.
        Medicine. 2019; 98: 44
        • Balachandran VP
        • Gonen M
        • Smith JJ
        • et al.
        Nomograms in oncology: more than meets the eye.
        Lancet Oncol. 2015; 16: e173-e180
        • Jin S
        • Wang B
        • Zhu Y
        • et al.
        Log Odds Could Better Predict Survival in Muscle-Invasive Bladder Cancer Patients Compared with pN and Lymph Node Ratio.
        J Cancer. 2019; 10: 249-256
        • Charlson ME
        • Szatrowski TP
        • Peterson J
        • et al.
        Validation of a combined comorbidity index.
        J Clin Epidemiol. 1994 Nov; 47: 1245-1251
        • Schoenfeld David.
        Partial Residuals for The Proportional Hazards Regression Model.
        Biometrika. 1982; 69: 239-241
        • Iasonos A
        • Schrag D
        • Raj GV
        • et al.
        How to build and interpret a nomogram for cancer prognosis.
        J Clin Oncol. 2008; 26: 1364-1370
        • Alba AC
        • Agoritsas T
        • Walsh M
        • et al.
        Discrimination and calibration of clinical prediction models: users' guides to the medical literature.
        JAMA. 2017; 318: 1377-1384
        • Pencina MJ
        • D'Agostino Sr, RB
        • D'Agostino Jr, RB
        • et al.
        Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond.
        Stat Med. 2008; 27 (discussion 207–12): 157-172
        • Vickers AJ
        • Van Calster B
        • Steyerberg EW.
        Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests.
        BMJ. 2016; 352: i6
        • Williams SB
        • Huo J
        • Chu Y
        • et al.
        Cancer and All-cause Mortality in Bladder Cancer Patients Undergoing Radical Cystectomy: Development and Validation of a Nomogram for Treatment Decision-making.
        Urology. 2017 Dec; 110: 76-83
        • Wang J
        • Wu Y
        • He W
        • et al.
        Nomogram for predicting overall survival of patients with bladder cancer: A population-based study.
        The International Journal of Biological Markers. 2020; 35: 29-39
        • Rink M
        • Crivelli JJ
        • Shariat SF
        • et al.
        Smoking and bladder cancer: A systematic review of risk and outcomes.
        Eur Urol Focus. 2015; 1: 17-27
        • Lammers RJ
        • Witjes WP
        • Hendricksen K
        • et al.
        Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer.
        Eur Urol. 2011; 60: 713-720
        • Rink M
        • Zabor EC
        • Furberg H
        • et al.
        Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy.
        Eur Urol. 2013; 64: 456-464
        • Koch M
        • Hill GB
        • McPhee MS.
        Factors affecting recurrence rates in superficial bladder cancer.
        J Natl Cancer Inst. 1986; 76: 1025-1029
        • Chu WC
        • Chen CH.
        Smoking behavior and survival outcomes in bladder cancer patients.
        Urol Sci. 2020; 31: 123-130
        • Prakash G
        • Pal M
        • Odaiyappan K
        • et al.
        Bladder cancer demographics and outcome data from 2013 at a tertiary cancer hospital in India.
        Indian J Cancer. 2019 Jan-Mar; 56: 54-58
        • Gupta P
        • Jain M
        • Kapoor R
        • et al.
        Impact of age and gender on the clinicopathological characteristics of bladder cancer.
        Indian J Urol. 2009 Apr; 25: 207-210